Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner.
about
Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugsTrial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyConnecting the Dots: From DNA Damage and Repair to AgingTargeting the Checkpoint to Kill Cancer CellsDNA damage response and prostate cancer: defects, regulation and therapeutic implicationsMolecular pathways: targeting the dependence of mutant RAS cancers on the DNA damage responsePerspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancerDrugging the addict: non-oncogene addiction as a target for cancer therapyChemical strategies for development of ATR inhibitorsA synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancersWild-type RAS: keeping mutant RAS in CHK.Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970Defining a tissue stem cell-driven Runx1/Stat3 signalling axis in epithelial cancer.Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.RPA inhibition increases replication stress and suppresses tumor growth.Causes and consequences of replication stress.ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition.Analysis of protein dynamics at active, stalled, and collapsed replication forks.Inferring the temporal order of cancer gene mutations in individual tumor samplesTargeting lung cancer through inhibition of checkpoint kinases.Protection from UV-induced skin carcinogenesis by genetic inhibition of the ataxia telangiectasia and Rad3-related (ATR) kinase.Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATRSelective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.The Overexpression of FEN1 and RAD54B May Act as Independent Prognostic Factors of Lung Adenocarcinoma.An extra allele of Chk1 limits oncogene-induced replicative stress and promotes transformation.Chk'ing p53-deficient breast cancersSynthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cellsDistinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S PhaseThe novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapyATR Mutations Promote the Growth of Melanoma Tumors by Modulating the Immune Microenvironment.Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.Effective intra-S checkpoint responses to UVC in primary human melanocytes and melanoma cell linesThe molecular pathogenesis of colorectal cancer and its potential application to colorectal cancer screeningHarnessing synthetic lethal interactions in anticancer drug discoveryA cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations.Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors.Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776
P2860
Q24610287-2925ED64-8B38-44F7-921B-B77AA0711966Q26745686-B372FFA3-363E-4692-9C55-67BE1BB26518Q26750854-F481221D-1B4F-47E5-BA10-3F032AC0AED4Q26795781-EECE9339-5CEE-47A9-810C-FEC23EA31917Q26829155-57AB0738-2052-490F-A948-FA3472CBC797Q27014080-07E090CD-1487-45FA-8B24-73374130FD2AQ28066320-A148EEE8-C77A-4221-A4A6-418D3C21F1FBQ28079559-B0140A45-547B-4B5F-8371-27C8C010A74EQ28239738-CAF4361B-59DE-4A49-890D-02B7604021B4Q28271944-AA9B537A-20B2-40D5-80EB-4DC78B08ED26Q33731697-84DA093E-AB95-4021-A8DE-C14356D0EB33Q33778215-F09451B2-836A-49BC-A973-ED6E27FA2804Q34062570-88E73E80-1B01-4116-820E-894E58122885Q34221860-1FD32FCA-9AE6-4C20-A45F-C86663F488ADQ34303695-7A496111-0FDE-4342-831E-93919A93573CQ34309214-8E649E5A-738C-435E-99A3-B8F38C2DA118Q34362555-B4807413-1F47-495A-ABA6-31FC55FB5411Q34394094-7AF1CE44-BC86-4D55-BF81-4FFB71A8A49FQ34614944-8A261798-BF4A-42BD-9A1E-7D25F84BB940Q35023976-23730315-1CB6-4297-8B80-EDB8E2BEA8CFQ35080080-4E95FB27-11B6-47F3-BDB8-D1C0AB08BE5BQ35106921-8FBC6D32-6639-4D74-B1A7-89AF1EDEAB23Q35128547-9427D258-68BA-41FB-AF91-6EA4B5DD2843Q35171016-68D75C43-38AF-4B41-9F9B-6803668F3182Q35640593-207DD4ED-FEBB-4314-A130-B4C146788220Q35737519-9B73AED2-5AFE-42EA-BDCA-4FBDA8F7A018Q35797402-17F777F0-CAC5-4D9A-B44D-65B5FA7BA63DQ35825997-654B44C4-2E43-42A4-8BD3-D1E4FBF670AAQ35858171-D16C64C4-D9AE-4708-91AE-4B98A33425FDQ36054977-2EDD6506-4790-4FB4-906E-4914E5E24FAEQ36075291-A926583B-A1DA-4EFD-9EA9-11BC9C348729Q36289912-6D8022CF-4808-40FC-89BD-482E4F19F319Q36301027-8C94C06E-CE21-41A8-BA9F-2DAEF22F8239Q36525188-6DD1A964-A06F-4511-B948-A8898DD32DF7Q36556389-895ACE6A-DE26-463C-8E8D-032713261733Q36656549-B2AEE924-CE3F-419F-A7DE-11AE72F4239EQ36839571-94CD5ECC-D787-44C9-A241-24C4BDF4CB4FQ36908567-E0F065A8-C05D-40E9-AB5E-FF0E7452E122Q36972697-92475774-4D7F-45EA-B29B-FAC846AD2775Q37100166-FF5AB725-D5C2-4C99-A633-C4F721D796D7
P2860
Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Combining ATR suppression with ...... in a dosage-dependent manner.
@ast
Combining ATR suppression with ...... in a dosage-dependent manner.
@en
Combining ATR suppression with ...... in a dosage-dependent manner.
@nl
type
label
Combining ATR suppression with ...... in a dosage-dependent manner.
@ast
Combining ATR suppression with ...... in a dosage-dependent manner.
@en
Combining ATR suppression with ...... in a dosage-dependent manner.
@nl
prefLabel
Combining ATR suppression with ...... in a dosage-dependent manner.
@ast
Combining ATR suppression with ...... in a dosage-dependent manner.
@en
Combining ATR suppression with ...... in a dosage-dependent manner.
@nl
P2093
P2860
P1433
P1476
Combining ATR suppression with ...... in a dosage-dependent manner.
@en
P2093
Amy C Durham
Barzin Y Nabet
David W Schoppy
Eric J Brown
Kevin D Smith
Oren Gilad
Ryan L Ragland
P2860
P304
P356
10.1158/0008-5472.CAN-10-2286
P407
P577
2010-11-23T00:00:00Z